© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 4, 274-283,
February 20, 2002
© 2002 Oxford University Press
ARTICLE |
Effects of Raloxifene After Tamoxifen on Breast and Endometrial Tumor Growth in Athymic Mice
Affiliations of authors: R. M. O'Regan (Division of Hematology/Oncology), C. Gajdos, A. De Los Reyes, W. Park, A. W. Rademaker, V. C. Jordan (Robert H. Lurie Comprehensive Cancer Center), Northwestern University, Chicago, IL; R. C. Dardes, Department of Gynecology, Federal University of São Paulo, Brazil.
Correspondence to: V. Craig Jordan, Ph.D., DSc., Robert H. Lurie Comprehensive Cancer Center and Northwestern University Medical School, Olson, Rm. 8258, 303 E. Chicago Ave., Chicago, IL 60611 (e-mail: vcjordan{at}northwestern.edu.
Background: In patients with early-stage breast cancer, 5 years of treatment with the selective estrogen receptor modulator (SERM) tamoxifen reduces breast cancer recurrence and mortality, whereas more than 5 years of tamoxifen does not further reduce breast cancer recurrence and doubles the risk of endometrial cancer. We evaluated the effects on tumor growth of raloxifene, another SERM, after tamoxifen treatment in mouse models of breast and endometrial cancers. Methods: Athymic, ovariectomized mice were bitransplanted with tumors derived from human breast cancer and endometrial cancer cells that either were tamoxifen-naive or had been exposed to tamoxifen for short (6 months) or long (>5 years) terms. The effects of raloxifene (two dose levels) and tamoxifen on tumor growth in the presence and absence of low-dose estrogen were evaluated. All statistical tests were two-sided. Results: Raloxifene was less effective than tamoxifen in blocking the stimulatory effects of low-dose estrogen on the growth of tamoxifen-naive breast (P<.001) and endometrial (P = .001) tumors. Raloxifene and tamoxifen had similar inhibitory effects on the growth of short-term tamoxifen-exposed breast tumors. Raloxifene and tamoxifen had similar stimulatory effects on the growth of breast and endometrial tumors that had been exposed to at least 5 years of tamoxifen. However, neither drug blocked the stimulatory effects of estrogen on the growth of these tumors. Raloxifene was less effective than tamoxifen (P<.001) in blocking the stimulatory effects of estrogen on endometrial tumors that had been exposed to tamoxifen in the past. Conclusions: Raloxifene and tamoxifen had similar effects on these mouse models of tamoxifen-naive and tamoxifen-resistant breast and endometrial cancer. Treatment with raloxifene following 5 years of adjuvant tamoxifen may not further decrease breast cancer recurrence and may increase endometrial cancer incidence.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. C. Jordan The 38th David A. Karnofsky Lecture: The Paradoxical Actions of Estrogen in Breast Cancer--Survival or Death? J. Clin. Oncol., June 20, 2008; 26(18): 3073 - 3082. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan and B. W. O'Malley Selective Estrogen-Receptor Modulators and Antihormonal Resistance in Breast Cancer J. Clin. Oncol., December 20, 2007; 25(36): 5815 - 5824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Gralow Bone Density in Breast Cancer: When to Intervene? J. Clin. Oncol., August 1, 2007; 25(22): 3194 - 3197. [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Michaud and S. Goodin Cancer-treatment-induced bone loss, part 2 Am. J. Health Syst. Pharm., March 15, 2006; 63(6): 534 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Fabian and B. F. Kimler Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Osipo, H. Liu, K. Meeke, and V. C. Jordan The Consequences of Exhaustive Antiestrogen Therapy in Breast Cancer: Estrogen-Induced Tumor Cell Death Experimental Biology and Medicine, September 1, 2004; 229(8): 722 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Liu, E.-S. Lee, C. Gajdos, S. T. Pearce, B. Chen, C. Osipo, J. Loweth, K. McKian, A. De Los Reyes, L. Wing, et al. Apoptotic Action of 17{beta}-Estradiol in Raloxifene-Resistant MCF-7 Cells In Vitro and In Vivo J Natl Cancer Inst, November 5, 2003; 95(21): 1586 - 1597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Hillner, J. N. Ingle, R. T. Chlebowski, J. Gralow, G. C. Yee, N. A. Janjan, J. A. Cauley, B. A. Blumenstein, K. S. Albain, A. Lipton, et al. American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer J. Clin. Oncol., November 1, 2003; 21(21): 4042 - 4057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kawakami, M. Kawakami, S. R. Husain, and R. K. Puri Effect of Interleukin (IL)-4 Cytotoxin on Breast Tumor Growth after in Vivo Gene Transfer of IL-4 Receptor {alpha} Chain Clin. Cancer Res., May 1, 2003; 9(5): 1826 - 1836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. X.-D. Song, L. M. Berstein, and R. J. Santen RESPONSE: Re: Effect of Long-Term Estrogen Deprivation on Apoptotic Responses of Breast Cancer Cells to 17{beta}-Estradiol and The Two Faces of Janus: Sex Steroids as Mediators of Both Cell Proliferation and Cell Death J Natl Cancer Inst, August 7, 2002; 94(15): 1173 - 1174. [Full Text] [PDF]
|
|
|
|
|
|
R. T. Chlebowski, N. Col, E. P. Winer, D. E. Collyar, S. R. Cummings, V. G. Vogel III, H. J. Burstein, A. Eisen, I. Lipkus, and D. G. Pfister American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition J. Clin. Oncol., August 1, 2002; 20(15): 3328 - 3343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Sporn Hobson's Choice and the Need for Combinations of New Agents for the Prevention and Treatment of Breast Cancer J Natl Cancer Inst, February 20, 2002; 94(4): 242 - 243. [Full Text] [PDF]
|
|